Adolfo Garcia-Sastre, PhD
img_Adolfo Garcia-Sastre
DIRECTOR GLOBAL HEALTH AND EMERGING PATHOGENS INSTITUTE
PROFESSOR | Microbiology
PROFESSOR | Medicine, Infectious Diseases
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Antivirals, Biodefense, Cellular Immunity, Cytokines, Gene Expressions, Gene Regulation, Gene Therapy, Immune Antagonism, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Interferon Resistance, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, RNA Transport & Localization, Trafficking, Transcription Factors, Transcriptional Activation and Repression, Vaccine Development, Virulence Genes, Viruses and Virology
Multi-Disciplinary Training Area
Immunology [IMM], Microbiology [MIC]
The Garcia-Sastre Laboratory is focused on exploring virus-host interactions with an emphasis on virus regulation of innate and adaptive immune responses. The outcome of these interactions not only determines disease severity but also influences the development of protective immunity resulting from viral infection and/or vaccination. The team has developed several techniques (reverse genetics), which allow for the genetic manipulation of the genomes of several virus families including influenza virus and Newcastle disease virus. Other viruses being studied include Zika virus, Dengue virus, West Nile virus, and Crimean-Congo hemorrhagic fever virus. These techniques are currently being used in several research areas including: i) characterization of virus-encoded virulence factors, ii) identification of virus-encoded antagonists of the interferon system, iii) virus replication and gene expression, iv) immune regulation of influenza replication, and v) vaccine development. Reverse genetics are also being utilized to generate virus vectors based on influenza virus and Newcastle disease virus. These viruses are effective inducers of humoral and cellular immune responses. Live attenuated influenza virus vaccines are being generated by genetic modification of the influenza virus-encoded interferon antagonist that was originally identified by the laboratory. Also, recombinant viruses can be produced that express protective antigens of other pathogens for which no safe attenuated vaccine strains are available.

PhD, University of Salamanca

Publications

Selected Publications

Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. Constantino López-Macías, Martha Torres, Brenda Armenta-Copca, Niels H. Wacher, Laura Castro-Castrezana, Andrea Alicia Colli-Domínguez, Tania Rivera-Hernández, Alejandro Torres-Flores, Matilde Damián-Hernández, Luis Ramírez-Martínez, Georgina Paz De la Rosa, Oscar Rojas-Martínez, Alejandro Suárez-Martínez, Gustavo Peralta-Sánchez, Claudia Carranza, Esmeralda Juárez, Horacio Zamudio-Meza, Laura E. Carreto-Binaghi, Mercedes Viettri, Damaris Romero-Rodríguez, Andrea Palencia, Edgar Reyna-Rosas, José E. Márquez-García, David Sarfati-Mizrahi, Weina Sun, Héctor Elías Chagoya-Cortés, Felipa Castro-Peralta, Peter Palese, Florian Krammer, Adolfo García-Sastre, Bernardo Lozano-Dubernard. Vaccine

Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA. Alexandra Sakai, Gagandeep Singh, Mahsa Khoshbakht, Scott Bittner, Christiane V. Löhr, Randy Diaz-Tapia, Prajakta Warang, Kris White, Luke Le Luo, Blanton Tolbert, Mario Blanco, Amy Chow, Mitchell Guttman, Cuiping Li, Yiming Bao, Joses Ho, Sebastian Maurer-Stroh, Arnab Chatterjee, Sumit Chanda, Adolfo García-Sastre, Michael Schotsaert, John R. Teijaro, Hong M. Moulton, David A. Stein. Molecular Therapy Nucleic Acids

The C-terminal amino acid motifs of NS1 protein affect the replication and virulence of naturally NS-truncated H1N1 canine influenza virus. Pingping Wang, Jianing Guo, Yefan Zhou, Min Zhu, Senbiao Fang, Fanyuan Sun, Chongqiang Huang, Yaohui Zhu, Huabo Zhou, Boyu Pan, Yifeng Qin, Kang Ouyang, Zuzhang Wei, Weijian Huang, Adolfo García-Sastre, Ying Chen. Emerging Microbes and Infections

View All Publications

Adolfo Garcia-Sastre, PhD

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Garcia-Sastre during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Synairgen
  • Accurius
  • Pfizer Inc.
  • 7 Hills Pharma LLC
  • Avimex
  • Esperovax Inc
  • Applied Biological Laboratories Inc
  • Paratus
  • Pharmamar

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • ContraFect Corporation
  • Vivaldi
  • Amovir
  • Curelab oncology
  • Curelab veterinary
  • Pagoda Genomics

Founder/Co-Founder/Partner

  • Amovir
  • Vaxalto
  • Pagoda Genomics
  • CastleVax Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.